Search clinical trials for: Locally advance

Total 24503 results

AP Biosciences Inc.

Not yet recruiting

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies (APT-CUBE)

Esophageal Squamous Cell Carcinoma (ESCC) | Locally Advanced or Metastatic Solid Tumors | Non Small Cell Lung Cancer (NSCLC) | Head and Neck Squamous Cell Carcinoma (HNSCC)
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Breast Cancer | Solid Tumor

China
University Hospital, Clermont-Ferrand

Not yet recruiting

PAncreas Borderline and Locally Advanced Snapshot Study (PALASS)

Pancreatic Cancer

France
Sun Yat-sen University

Recruiting

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Stage III Non-small Cell Lung Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

Esophageal Squamous Cell Carcinoma | Locally Advanced Carcinoma

China
OncoSil Medical Limited

Recruiting

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma (TRIPP-FFX)

Locally Advanced Pancreatic Cancer

Spain, Belgium, United Kingdom, Italy, Australia
The First Hospital of Jilin University

Recruiting

A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)

PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer

China
Allist Pharmaceuticals, Inc.

Not yet recruiting

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

NSCLC
Maastricht University Medical Center
Sun Pharmaceutical Industries Limited

Recruiting

Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study

Carcinoma | Carcinoma, Basal Cell | Skin Cancer | Basal Cell Nevus Syndrome | Neoplasms, Basal Cell | Basal Cell Carcinoma | Locally Advanced Basal Cell Carcinoma | Metastatic Basal Cell Carcinoma | Gorlin Syndrome | Basal Cell Tumor | Neoplasm of Skin

Netherlands
MARILIA ALBANEZI BERTOLAZZI

Recruiting

Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.

Locally Advanced Cervical Carcinoma | Premature Ovarian Failure

Brazil
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

Breast Cancer | Locally Advanced or Metastatic Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Hoffmann-La Roche

Recruiting

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Squamous Cell Carcinoma of the Head and Neck

Korea, Republic of, United States, France, Australia, Israel, Spain, United Kingdom, Switzerland
AstraZeneca

Recruiting

A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia (NIS durvalumab)

NSCLC, Non-small-cell Lung Carcinoma

Russian Federation
Northwestern University
National Cancer Institute (NCI)

Recruiting

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

Locally Advanced Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Oncocytic Carcinoma

United States
First Affiliated Hospital of Zhejiang University

Not yet recruiting

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

Advanced Biliary Tract Carcinoma

China
Yanhong Deng
GeneCast Biotechnology Co., Ltd.

Recruiting

Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer (SILAR)

Rectal Cancer

China
Zhejiang Provincial People's Hospital

Recruiting

Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC

Head and Neck Squamous Cell Carcinoma

China
OBI Pharma, Inc

Recruiting

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (EGFR)

Non-small Cell Lung Cancer

Taiwan
Tvardi Therapeutics, Incorporated

Recruiting

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (LEADS)

Atopic Dermatitis

United States
Shanghai Zhongshan Hospital

Recruiting

Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer

China
Universität des Saarlandes

Recruiting

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

Head and Neck Squamous Cell Carcinoma

Germany
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Non Small Cell Lung Cancer

China
Sun Yat-sen University
Hunan Cancer Hospital; Beijing Biostar Pharmaceuticals Co., Ltd.

Recruiting

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms | Locally Advanced or Metastatic Breast Cancer

China
Shanghai Proton and Heavy Ion Center

Recruiting

Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer

Pancreatic Cancer Non-resectable

China
Jiangsu Cancer Institute & Hospital

Recruiting

Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus (SCALE-2)

Locally Advanced Esophageal Carcinoma

China
The Fourth Affiliated Hospital of Zhejiang University...
Second Affiliated Hospital, School of Medicine, Zhejiang University

Recruiting

Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI)

Rectal Neoplasms

China
Jiangsu Cancer Institute & Hospital

Not yet recruiting

RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2

Biliary Tract Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

China
University of Miami

Recruiting

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer (SMART TNT)

Locally Advanced Rectal Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma | Locally Advanced Pancreatic Carcinoma

United States, Canada
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Neoadjuvant Therapy | High Risk Prostate Cancer | Locally Advanced Prostate Cancer | Intense Endocrine Therapy

China
Leiden University Medical Center
Erasmus Medical Center; HollandPTC

Recruiting

PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer (PROTECT)

Uterine Cervical Neoplasms | Locally Advanced Cervical Carcinoma

Netherlands
Bio-Thera Solutions

Recruiting

Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009

Locally Advanced/Metastatic Solid Tumours

China
Fudan University

Not yet recruiting

Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms | Locally Advanced or Metastatic Breast Cancer
iTeos Belgium SA

Recruiting

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Metastatic NSCLC - Non-Small Cell Lung Cancer | Locally Advanced NSCLC - Non-Small Cell Lung Cancer

United Kingdom, Spain, Belgium, France, United States, Switzerland, Italy, Germany, Canada, Czechia, Poland
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, Canada, Spain
Shanghai Zhongshan Hospital

Not yet recruiting

A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer

Gastric Cancer
Sun Yat-sen University

Recruiting

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

Induction Chemotherapy | Locally Advanced Nasopharyngeal Carcinoma | PD-L1 | Envafolimab

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors

Locally Advanced or Metastatic Urinary Tumors | Other Solid Tumors

China
Shanghai Henlius Biotech

Recruiting

A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma (HLX301)

Lymphoma | Advanced Tumors | Metastatic Tumors

China
Wuhan Union Hospital, China

Not yet recruiting

Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric

Radiotherapy | Immunotherapy | Gastric/Gastroesophageal Junction Adenocarcinoma
Heath Skinner

Recruiting

Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

Oropharynx Cancer

United States
Xijing Hospital

Not yet recruiting

Immune Combined Targeted and Chemotherapy in Perioperative Treatment of Locally Advanced Gastric Cancer (ICTCPTLAGC)

Gastric Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors

Solid Tumor | Locally Advanced or Metastatic Digestive Tract Tumors

China
Nuvalent Inc.

Recruiting

A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Metastatic Solid Tumor | Locally Advanced Solid Tumor

Canada, United States, Australia, Taiwan, Spain, United Kingdom, Korea, Republic of, Italy, France, Singapore, Netherlands
Antonio Giordano, MD
Cardiff Oncology

Recruiting

Onvansertib + Paclitaxel In TNBC

Breast Cancer | Metastatic Breast Cancer | Inflammatory Breast Cancer | Invasive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Hormone Receptor Negative Breast Carcinoma | Hormone Receptor/Growth Factor...

United States
Gilead Sciences
Merck Sharp & Dohme LLC

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

Triple Negative Breast Cancer | PD-L1 Positive

United States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

Triple Negative Breast Cancer | PD-L1 Negative

United States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more

Search clinical trials for: Locally advance

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations